GlassScriptPhysician profile
John R Nolen, JR.
NPI 1649213083
$5,833.62
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,707 · 2020: $754 · 2021: $1,376 · 2022: $1,636 · 2023: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $710.75 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $672.31 | 2019-2023 | Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $387.30 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $377.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $329.82 | 2019-2022 | |
| Pfizer INC. | $316.13 | 2019-2023 | |
| Abbvie INC. | $301.86 | 2020-2023 | |
| Abbott Laboratories | $238.47 | 2021-2023 | Freestyle Libre |
| Supernus Pharmaceuticals, INC. | $195.63 | 2019-2023 | |
| Astellas Pharma US INC | $192.19 | 2019-2022 | |
| Horizon Therapeutics Plc | $172.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.06 | 2022-2023 | |
| Amgen INC. | $148.66 | 2019-2023 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $145.66 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nolen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.